Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...

Axsome Therapeutics (AXSM) announced that the EMERGE Phase 3 trial of SYMBRAVO in patients experiencing inadequate response to oral CGRP ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Childhood neuroblastoma is often a fatal disease. A new approach using a combination of two drugs shows promise in reducing ...

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative ...

"Although PD-L1 testing is standard in some cases, many patients end up on Keytruda without really benefiting,” said Faith ...

Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on ...

Half of all pancreatic cancer patients live less than a year after diagnosis. But researchers say there is potential for ...

Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus ...

President Donald Trump issued an executive order last week for a team to study the use of antidepressants in children.